All In Biotech

Free tool

FAERS Monitor: Kyzatrex

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 213953 or its brand name (Kyzatrex, Testosterone Undecanoate). Reports on generic versions are filed under their own applications.

Reports

259

Serious

209

81% of reports

Hospitalization

94

Death reported

20

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use29
  • drug abuse13
  • asthma10
  • atrial fibrillation10
  • erectile dysfunction9
  • fatigue9
  • weight decreased9
  • duodenal ulcer8
  • erosive duodenitis8
  • faeces discoloured8
  • headache8
  • hypertension8
  • pneumonia haemophilus8
  • polycythaemia8
  • product use in unapproved indication8

Reports by year received

View as table
YearReports
20042
20051
20061
20093
20106
20112
20129
20135
20144
201512
20167
20175
201822
20198
20209
202114
202211
202319
202424
202561
202634

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,900 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
pneumonia haemophilusSignal81360.5683.79,394
erosive duodenitisSignal8821.1413.65,701
polycythaemiaSignal8316.1159.62,200
duodenal ulcerSignal892.246.6633
faeces discolouredSignal830.015.2196
erectile dysfunctionSignal928.515.0212
drug abuseSignal1312.77.5129
atrial fibrillationSignal108.34.558
asthmaSignal107.23.947
hypertensionSignal83.11.69
off label useSignal292.71.930
product use in unapproved indicationSignal82.61.37
weight decreasedSignal92.61.48
headache81.00.50
fatigue90.90.50

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.